Introduction
For many years, the process of oncogenesis has been described as a deregulation of cellular proliferation leading to the expansion of a particular cell population. More precisely, however, the expansion of a tumor (or any tissue) is directly related to the dierence of the rates of proliferation and cell death (Bresciani et al., 1974) . This idea suggests that defects in the apoptosis machinery may contribute to the malignant phenotype found in some forms of cancer. This seems to be true in chronic myelogenous leukemia (CML), where rather than deregulated cell growth, increased resistance to cell death is observed (Koeer and Golde, 1981; Strife and Clarkson, 1988; Stryckmans et al., 1976) .
This so-called myeloacummulative leukemia is the outcome of a translocation between chromosomes 9 and 22, which generates the Bcr ± Abl tyrosine kinase by the fusion of bcr sequences upstream of the second exon of c-abl. This chimeric protein occurs in Philadelphia chromosome-positive leukemias and exists in two dierent forms: a 210 kDa protein is detected in CML and a 185 kDa fusion protein in acute lymphocytic leukemia (ALL). In both cases, Bcr ± Abl has been implicated in cellular transformation and inhibition of apoptosis (Carlesso et al., 1994; Cortez et al., 1995) .
The transforming potential of this oncoprotein is related to its tyrosine kinase activity (Lugo et al., 1990; McLaughlin et al., 1989) and also to the coupling of downstream signal transduction pathways, which is provided by multiple functional domains (Afar et al., 1994; Cortez et al., 1995; Goga et al., 1995; Muller et al., 1991; Pendergast et al., 1993) . Point mutations in the autophosphorylation site in the SH1 domain or in the conserved FLVRES motif within the SH2 domain impair the potential of the Bcr ± Abl molecule to transform ®broblasts (Afar et al., 1994) . The two single mutants, but not a double mutant, can be complemented in their transforming ability by overexpression of c-myc (Afar et al., 1994) .
Despite the vast literature on the biochemical signals triggered by Bcr ± Abl, very little is known about the mechanism by which Bcr ± Abl inhibits apoptosis. We therefore developed an experimental model in which HL-60, a transformed promyelocytic cell line that is very sensitive to a variety of apoptosis-inducing stimuli, ectopically expresses the p185 isoform of Bcr ± Abl. Here, we describe the potent anti-apoptotic eect of Bcr ± Abl in HL-60 cells and the possible role of Bcl-2 family members in this eect. We show that ectopic expression of Bcr ± Abl leads to the upregulation of Bcl-x L in a variety of cell lines and propose that this contributes to, but does not account for, the overall anti-apoptotic eect of Bcr ± Abl.
Results

Multi-drug resistance of HL-60 cells expressing Bcr ± Abl
Expression of Bcr ± Abl in HL60 cells was achieved by infection with recombinant retroviruses and selection in G418-containing medium and con®rmed by Western blot (Figure 1b ). Bcr ± Abl expression converted this apoptosis-sensitive line into cells extremely resistant to apoptosis, regardless of the inducing agent (Figure 2 ). DNA damaging agents (Ara-C, VP16, VM26, camptothecin), protein (CHX) or RNA (Act-D) synthesis inhibitors, cytoskeleton disrupting drugs (Cytochalasin B, vincristine sulfate, nocodazol), protein kinases inhibitors (staurosporine), direct activators of the caspases (anti-CD95 antibodies), and other agents, were compared for their eects on Bcr ± Abl-positive and -negative HL-60 cells (Figures 2 and 3) . Apoptosis was determined after 12 or 24 h, depending on the inducing agent (fast6slow death kinetics). In all cases tested, apoptosis was dramatically inhibited by the expression of the Bcr ± Abl tyrosine kinase (Figures 2 and 3) . Some of these treatments, as expected, changed the cell cycle pro®le of HL-60.Bcr ± Abl cells such that surviving cells were arrested in dierent phases of the cell cycle (e.g. CHX-treated cells accumutated in G1 while nocodazoltreated cells arrested in G2 ± Figure 2 ). Nevertheless, dramatic protection was observed in each of these cases. This suggests that the protection of Bcr ± Abl is independent of any one cell cycle phase.
To determine whether mutations at the autophosphorylation site (Y793F), at the conserved FLVRES motif within the SH2 domain (R552L) of Bcr ± Abl, or at both of these sites (L552 ± F793; DM) interfere with the resistance to apoptosis conferred by this molecule, mutant Bcr ± Abl proteins were also expressed in HL-60 cells. These mutants have been shown to be unable to transform rodent ®broblasts (Afar et al., 1994) . More recently, it was shown that the single mutants render myeloid and lymphoid cell lines growth factor independent (Goga et al., 1995) . Each of the HL-60 bulk lines obtained were found to express similar levels of Bcr ± Abl (Figure 1b ). In every case tested, Bcr ± Abl mutants were able to protect HL-60 cells from apoptosis to the same extent observed for the wild-type molecule (Figure 3 ). In the case of apoptosis induced by anti-CD95 antibodies, the expression of CD95 was monitored by FACS analysis and proved to be similar in HL-60.vector and every HL-60.Bcr ± Abl expressing cell population (not shown).
Resistance to apoptosis is inhibited by antisense oligonucleotides directed against Bcr ± Abl
To con®rm that the anti-apoptotic eect observed in HL-60.Bcr ± Abl cells was in fact due to the expression of Bcr ± Abl, these cells were treated with antisense (AS) oligodeoxynucleotides corresponding to the translation start site of bcr and then examined for resistance to apoptosis. In K562 cells, AS-bcr-induced down regulation of Bcr ± Abl protein levels is associated with reduction in the resistance to apoptosis (Martiat et al., 1993; McGahon et al., 1994; Szcylik et al., 1991) . Likewise, as exempli®ed for HL-60.Bcr ± Abl DM cells (Figure 4a ), down regulation of Bcr ± Abl after treatment with AS-bcr restored the susceptibility to VP-16-induced apoptosis, as detected by the TUNEL assay (Figure 4b ). Similar results were obtained with HL-60.Bcr ± Abl WT, HL-60.Bcr ± Abl RL and HL-60.Bcr ± Abl YF cells (data not shown). As a control for the speci®c eect of the ASbcr on the Bcr ± Abl molecule, we used HL-60 cells expressing a temperature-sensitive mutant of v-Abl (RK160) previously described to be resistant to apoptosis at the permissive (328C) but not at the restrictive (398C) temperature (McGahon et al., 1995b, and unpublished results) . Treatment of these cells with the AS-bcr did not alter the expression of v-Abl (not shown) nor aect the anti-apoptotic eect of v-Abl observed at 328C (Figure 4c ).
Expression of Bcr ± Abl decreases Bcl-2 and increases Bcl-x L levels Bcl-2 members are well known regulators of apoptosis. Bcl-2 and Bcl-x L protect from apoptosis whereas Bax increases susceptibility to apoptosis in dierent systems . We therefore compared the levels of these proteins in HL-60.vector and HL-60.Bcr ± Abl cells. HL-60.vector cells expressed considerable levels of Bcl-2 and Bax but not Bcl-x L (Figure 5a ). Interestingly, Bcl-2 protein was completely absent in HL-60 cells expressing the wild-type and the mutant Bcr ± Abl molecules ( Figure  5a ). In contrast, Bcl-x L levels were substantially elevated in HL-60.Bcr ± Abl cells. Bax expression was unaected by Bcr ± Abl. Upregulation of Bcl-x L was also observed in Bcr ± Abl-expressing BaF3, DAGM and 3T3 cells ( Figure 5b ).
Participation of Bcl-x L in Bcr ± Abl-mediated resistance to apoptosis
Since Bcr ± Abl upregulates the expression of the antiapoptotic protein Bcl-x L , we decided to investigate As a control for protein loading, the same blot was probed for actin (bottom panel) whether this eect contributed to Bcr ± Abl-mediated resistance to apoptosis. HL-60.Bcr ± Abl cells were treated for 60 h with antisense oligonucleotides corresponding to the translation start site of bcl-x and then examined for resistance to staurosporineinduced apoptosis. Bcl-x L expression was decreased by Figure 2 Anti-apoptotic eect of Bcr ± Abl. HL-60.vector and HL-60p185 bcr ± abl WT cells were treated for 12 or 24 h with dierent death-inducing agents and apoptosis estimated by cell cycle analysis. Numbers represent the percentage of cells with subdiploid DNA content Figure 3 Comparison of the anti-apoptotic eect of wild-type and mutant forms Bcr ± Abl. HL-60 cells expressing or not wild-type or mutant Bcr ± Abl proteins were treated with dierent concentrations of apoptosis-inducing agents or submitted to U.V. irradiation for dierent periods of time. The level of apoptosis in these cells were estimated by changes in light scattering properties 18 h after the initiated stimuli the treatment of cells with the antisense but not with sense or nonsense oligonucleotides ( Figure 6a ). Down regulation of Bcl-x L correlated with an increase in the sensitivity of HL-60.Bcr ± Abl cells to staurosporineinduced apoptosis (Figure 6b) . However, the level of apoptosis observed under this circumstance (around 28%) was less than that observed in the control HL-60.vector cells (always above 75%), suggesting that Bcl-x L is not the only component responsible for the Bcr ± Abl-mediated resistance to apoptosis. Similar results were obtained when HL-60.Bcr ± Abl cells were treated with a slightly dierent AS-bcl-x previously shown to interfere with the levels of Bcl-x L and to partially block CD40-mediated rescue of sIg-induced apoptosis in murine B cells (Wang et al., 1995) . To con®rm this hypothesis, we compared the level of protection conferred by overexpression of either Bcr ± Abl or Bcl-x L in HL-60 cells. HL-60.Bcl-x L cells expressed higher levels of Bcl-x L than did HL60. Bcr ± Abl cells (Figure 7a ). Nevertheless, HL-60.Bcl-x L cells showed a lower degree of resistance to apoptosis induced by three dierent agents than seen in HL-60.Bcr ± Abl cells (Figure 7b) . Therefore, overexpression of Bcl-x L did not fully mimic the eect of Bcr ± Abl in HL-60 cells.
Discussion
It has been shown in a variety of cell systems that oncogenic forms of the Abl tyrosine kinase induce transformation and confer resistance to apoptotic death. Substantial knowledge of the mechanism implicated in Abl-mediated transformation was provided during the past few years and involves an Abl tyrosine kinase-dependent activation of multiple biochemical signals (Cortez et al., 1995; Goga et al., 1995) . However, the interaction between oncogenic Abl and the cellular apoptotic machinery is far from being elucidated.
In order to investigate the mechanism involved in the anti-apoptotic eect of oncogenic Abl, HL-60 cells were infected with a retrovirus construct capable of expressing Bcr ± Abl. These cells were chosen for two reasons: ®rst, they are already transformed and do not require growth factors (GFs) for survival, and; second, they are very sensitive to a variety of apoptosis- inducing agents. Therefore, we speculated that the dierences in biochemical signals triggered by Bcr ± Abl in these transformed cells and the status quo of molecular interactions existing in wild-type HL-60 could potentially be related to molecules involved in the anti-apoptotic pathway. It has been proposed that GF-independence is one of the multiple steps of tumorigenesis and is directly related to the ability of certain GF to provide antiapoptotic signals (Adams and Cory, 1992; Canman et al., 1995) . Bcr ± Abl was shown to aord IL-3-dependent cells, such as 32D and BaF3 cells, GFindependence. This phenomenon was associated with the ability of Bcr ± Abl to confer resistance to apoptosis and, consequently, it linked a transformation potential to anti-apoptotic signaling. However, Pendergast and colleagues (Cortez et al., 1995) showed that a mutant Bcr ± Abl (D176 ± 427) that has an impaired transforming ability in these cells still retained the competence to rescue cells from IL-3 withdrawal-or g-irradiation-initiated apoptosis. Thus, Bcr ± Abl-induced resistance to apoptosis can occur independently from cellular transformation. We recently observed that the anti-apoptotic eect of Bcr ± Abl is independent of PI 3-kinase activity (Amarante-Mendes et al., 1997), which was previously shown to participate in the growth of Bcr ± Abl-positive cells (Skorski et al., 1995) and to be implicated in the resistance to apoptosis conferred by some GFs (Minshall et al., 1996; Yao and Cooper, 1995) . These observations suggest that the biochemical pathways involved in Bcr ± Abl-mediated transformation and protection from apoptosis may be either autonomous or complementary, but are probably not the same. Also, they suggest that the Bcr ± Abl- Expression of Bcr ± Abl in HL-60 cells conferred strong resistance to apoptosis regardless of the inducing agent. This suggests that Bcr ± Abl either acts at multiple points to prevent cell death or has one single target intimately associated with the central mechanism of the apoptotic machinery. This mechanism, which we refer to as the Executioner (Martin and Green, 1995), consists of members of a particular family of cysteine proteases, namely caspases (Alnemri et al., 1996) (also known as ICE/CED-3 family of proteases), acknowledged to be responsible for the cleavage of speci®c substrates leading to cellular demise. Recently, we observed that Bcr ± Abl works upstream of the activation of the caspases since it blocks proteolytic events associated with apoptosis, including proteolytic activation of caspase-3 and cleavage of PARP, fodrin and others (AmaranteMendes, GP; Martin SJ and Green DR unpublished observations). Bcr ± Abl was shown here to protect HL-60 cells from apoptosis in dierent phases of the cell cycle (Figure 2 ), since the protected cells were sometimes arrested in either G1 or G2/M as a consequence of the agent used.
Point mutations in the autophosphorylation site (Y793F) and/or in the phosphotyrosine binding motif (R552L) did not alter the ability of the Bcr ± Abl molecule to protect HL-60 cells from apoptosis. It was previously reported that both single and double mutants are defective in transforming ®broblasts (Afar et al., 1994) but the single mutants are fully capable of transforming hematopoietic cells (Cortez et al., 1995; Goga et al., 1995) . In contrast, the double mutant R552L/Y793F was shown to be uncapable of bone marrow transformation (Goga et al., 1995) and a triple mutant consisted of the same double mutation plus an additional mutation that inactivates the Grb-2-binding site (Y177F/R552L/Y793F) could not confer IL-3-independency or protect 32D cells from g-irradiation-induced apoptosis (Cortez et al., 1995) . However, the same triple mutant did protect BaF3 cells from g-irradiation and IL-3 withdrawal (Cortez et al., 1995) suggesting that dierent cells may provide alternative pathways for resistance to apoptosis initiated by Bcr ± Abl. In this regard, HL-60 would behave more like BaF3 than 32D or primary bone marrow cells. HL-60 cells expressing either of the mutant Bcr ± Abl molecules showed similar resistance to death as those expressing wild-type Bcr ± Abl, regardless of the stimulus and of the method used to evaluate cell death (Figure 3 and unpublished observations). These results suggest that in spite of being extremely sensitive to apoptosis, HL-60 cells provide a biochemical environment that complements the potential de®ciency of some mutant forms of Bcr ± Abl and may be of great value for unraveling the mechanisms that operate in Bcr ± Abl-mediated resistance to cell death. A possible candidate that could account for this complementation might be c-Myc since this molecule is overexpressed in HL-60 cells and shown to collaborate with the single Bcr ± Abl mutants in transforming ®broblast cells (Afar et al., 1994) .
All the stable transfectants described here exhibited a remarkable resistance to apoptosis which could be overcome by incubation of these cells with antisense oligonucleotides against the ®rst 18 bases of the translation start site of bcr, con®rming the dependency of the anti-apoptotic eect on Bcr ± Abl expression (Figure 4 ). Such oligonucleotides have previously been used to show that down regulation of Bcr ± Abl in the CML line K562 renders these cells susceptible to apoptosis (McGahon et al., 1994) . It is important to note that the anti-apoptotic phenotype seems to be dependent on a certain threshold level of Bcr ± Abl since the treatment with NS-bcr oligonucleotides nonspeci®cally down regulated the levels of Bcr ± Abl to around 40% without aecting the resistance to apoptosis.
Interestingly, both wild-type and mutant forms of Bcr ± Abl down regulated Bcl-2 and up regulated Bclx L , but did not aect the expression of Bax (Figure 5a ). Bcl-2 and Bcl-x L have distinguishable biological functions despite the fact that they share structural and functional homology. First, it has been shown that they have dierent preferences in binding to other Bcl-2 family members (e.g., Bcl-2 preferentially associates with Bax (Oltvai et al., 1993) and Bcl-x L with Bad (Yang et al., 1995) . Second, while it is still controversial as to whether Bcl-2 prevents CD95/Fas/ APO-1-mediated apoptosis (Itoh et al., 1993; Mandal et al., 1996; Memon et al., 1995; Strasser et al., 1995) , it is generally accepted that Bcl-x L inhibits this cell death pathway (Boise and Thompson, 1997) . Finally, NunÄ ez and co-workers have recently shown that Bcl-2 and Bcl-x L dierentially block apoptosis induced by chemotherapeutic drugs (Simonian et al., 1997) . Therefore, the shift from Bcl-2 to Bcl-x L in HL-60 cells expressing Bcr ± Abl might account for, at least, some of anti-apoptotic eects of the oncogenic Abl. Indeed, our results with AS-bcl-x support a role for this anti-apoptotic molecule in Bcr ± Abl-induced resistance to apoptosis in these cells (Figure 6 ).
In contrast, resistance to apoptosis in HL-60.Bcr ± Abl cells appears to be independent of Bcl-2 function, since the expression of Bcl-2 is down regulated to undetectable levels in these cells. This result contrasts with a previous observation suggesting that Bcr ± Abl acts through the expression of Bcl-2 (Sanchez Garcia and Grutz, 1995) . These authors showed that down regulation of bcl-2 mRNA by transfection of Bcr ± Ablexpressing BaF3 cells with a plasmid containing mouse bcl-2 in antisense orientation reverted the IL-3 independent phenotype of these cells. It is possible that in dierent cell lines, Bcr ± Abl would require the participation of either Bcl-x L or Bcl-2. However, we also detected reduced levels of Bcl-2 (not shown) and elevated expression of Bcl-x L (Figure 5b ) in Bcr ± Ablpositive BaF3 cells suggesting that similar Bcr ± Ablmediated anti-apoptotic mechanisms operate in both HL-60 and BaF3 cells. In this regard, it was recently suggested that inhibition of apoptosis in BaF3 cells by IL-3 occurs in two distinct levels, one of them independent of mRNA and protein synthesis and the other dependent on the induction of Bcl-x L expression (Leverrier et al., 1997) . Since Bcr ± Abl is capable of replacing the IL-3 anti-apoptotic signaling in these cells it is reasonable to assume that Bcr ± Abl could also work by two dierent mechanisms and therefore only part of its anti-apoptotic eect would be due to up regulation of Bcl-x L . This hypothesis is supported by the observation that overexpression of Bcl-x S in K562 cells, which is reportedly antagonistic to the antiapoptotic eect of Bcl-2 and Bcl-x L (Boise et al., 1993) , only partially reverts the resistance to apoptosis induced by chemotherapeutic drugs (Ray et al., 1996) . Indeed, we showed here that overexpression of Bcl-x L , despite increasing the resistance to apoptosis in HL-60 cells, did not fully mimic the anti-apoptotic eect of Bcr ± Abl in this cell line. Therefore, other signals probably also contribute to the Bcr ± Ablmediated anti-apoptotic phenotype. One possible candidate is the oncogene Ras, which was shown to be important in Bcr ± Abl-mediated transformation (Pendergast et al., 1993) and also to participate in the resistance to apoptosis observed in the CML line K562 (Sakai et al., 1994) and more recently in 32D.Bcr ± Abl cells (Cortez et al., 1996) . The fact that Bcr ± Abl modulated the expression of Bcl-x L in other cell types suggests a common anti-apoptotic pathway initiated by Bcr ± Abl.
Thus, there is a remarkable anti-apoptotic eect of Bcr ± Abl in HL-60 cells, independent of both the cell cycle and the expression of Bcl-2 and associated with, but not restricted to, an increase in Bcl-x L protein levels. This model may be useful to dissect the biochemical pathways involved in Bcr ± Abl-mediated resistance to apoptosis and, consequently, to gain insights into the molecular mechanisms that coordinate the apoptotic machinery of the cells. The potential knowledge derived from these studies may provide means to help the development of new strategies for therapy of Ph 1 -positive leukemias as well as other forms of cancer.
Materials and methods
Cell culture and reagents
HL-60 cells were cultured in RPMI-1640 supplemented with 5% FCS and 2 mM L-glutamine (RPMI-5). HL-60.Bcl-x L line was a generous gift from Dr Kapil Bhalla (Emory University School of Medicine, Atlanta, GA). DAGM cells expressing Bcr ± Abl were described elsewhere (Goga et al., 1995) . BaF3 and BaF3.p185 bcr ± abl cells were kindly provided by Dr Ann Marie Pendergast (Duke University Medical Center, Durham, NC) and were maintained in RPMI-5+10% of WEHI-3B conditioning media. C 2 and PA317 cells were cultured in IMDM supplemented with 10% FCS and 2 mM L-glutamine.
Etoposide (VP-16) and staurosporine were prepared as 100 mM and 1 mM solutions in dimethyl sulfoxide (DMSO), respectively. Actinomycin-D was prepared as as 1 mM stock solution in RPMI-1640. Cycloheximide (CHX) and ceramide (C6) were prepared in ethanol as 50 mM and 1 mM solutions, respectively. Anti-CD95 IgM mAb (Kamiya Biomedical Co., Thousand Oaks, CA) was prepared as 0.1 mg ml 71 stock solution in PBS.
Generation of retrovirus and production of Bcr ± Abl-expressing cell lines HL-60.Bcr ± Abl cells were obtained by retroviral infection with pSRaMSVp185 bcr ± abl tkneo plasmids (Afar et al., 1994) . Brie¯y, a combination of 5610 6 c2 and 5610 6 PA317 packaging cell lines (c+P) were electroporated (250 mV, 960 mFD) in the presence of 20 mg ml 71 of pSRaMSVtkneo carrying Bcr ± Abl p185 wild-type (WT), p185 R552L (RL; FLVRES mutant), p185 Y793F (YF; autophosphorylation mutant), or p185 L552 ± F793 (DM; double mutant) genes (Figure 1a ). Cells were cultured for 2 weeks in DMEM containing 10% iron-supplemented calf serum (Gibco), 2 mM L-glutamine and 8 mg ml 71 polybrene, and subsequently selected by their ability to grow in the presence of 0.4 mg ml 71 G418 (Gibco BRL). Resistant cells were expanded and served as the source of retrovirus. HL-60 cells were infected by co-culture with the virus-producing c+P cells, in the presence of 8 mg ml 71 polybrene. G418-resistant cells were maintained in RPMI-1640 supplemented with 5% FCS and 2 mM L-glutamine (RPMI ± FCS). The expression of Bcr ± Abl was con®rmed by Western blot analysis using an anti-c-Abl mAb (Ab-3; Oncogene Science) ( Figure 1B) .
Treatment with antisense oligonucleotides
The optimal conditions for Bcr ± Abl protein depletion in K562 cells was established previously (McGahon et al., 1994) . Bcr ± Abl-positive HL-60 cells were incubated for 60 h in the presence of 30 mM of either sense (S), antisense (AS) or nonsense (NS) phosphorothioate derivatised oligodeoxynucleotides (QCB, USA) corresponding to the ®rst 18 bases of the translation start site of bcr or bcl-x. Fresh oligonucleotides were added at 16, 32 and 48 h. Oligonucleotide sequences used were as follows: AS-bcr: 5'-GCCCACCGGGTCCACCAT-3'; NS-bcr: 5'-CGCGC CTC-GTCCCAAGCA-3'; S-bcl-x: 5'-ATGTCTCAGCA ACCGG-3'; AS-bcl-x: 5'-CCGGTTGCTCTGAGACAT-3'; NS-bcl-x: 5'-CTGAACGGAGACCCTT AG-3'.
Western blot analysis
Cells were harvested, washed once in cold PBS and resuspended in suspension buer (SB; 0.1 M NaCl, 0.01 M Tris-C1 pH 7.6, 0.001 M EDTA, 1 mg ml 71 aprotinin, 1 mg ml 71 leupeptin, 100 mg ml 71 PMSF, 1 mM NaNO 3 ). Equal amounts of SDS-sample buer 26(5% 2-ME, 4% SDS, 20% glycerol, 100 mM Tris-Cl ± pH 6.8) were immediately added and samples were boiled for 5 min. Protein content in the cell extracts were determined by the Bio-Rad microassay. Samples were resolved on SDS ± polyacrylamide gel, transferred to PVDF membranes and immunoblotted with either anti-c-Abl (c-abl (Ab-3), Oncogene Science) or anti-actin (clone C4 ± ICN Biomedicals, Inc., Costa Mesa, CA) monoclonal antibodies or with rabbit polyclonal antiserum raised against Bcl-2, Bcl-x or Bax (kindly provided by Dr John Reed, The Burnham Institute, La Lolla, CA). Reactions were detected with horseradish peroxidase-conjugated goat anti-mouse or mouse antirabbit antibody using an enhanced chemiluminescence system (ECL, Amersham). The NIH-Image software was used for densitometry analysis.
Determination of apoptosis
Apoptosis was assessed by several criteria. Percentage of cell death was calculated by changes in the light scattering properties due to reduction in cell size and increase in granularity (McGahon et al., 1995a) . DNA fragmentation was quanti®ed by cell cycle analysis of total DNA content as described elsewhere (Nicoletti et al., 1991) , with slight modi®cations. A total of 2610 5 cells were washed twice in PBS and resuspended in 0.25 ml of hypotonic¯uorochrome solution (50 mg ml 71 propidium iodide and 0.1% Triton X-100 in 0.1% sodium citrate). After 30 min at 48C in the dark, the¯uorescence of individual nuclei was measured using a FACScan¯ow cytometer (Becton-Dickinson, Mountain View, CA). The percentage of hypodiploid nuclei correlates with the extent of apoptosis in the sample. DNA breaks was measured by the TUNEL assay as previously described (McGahon et al., 1995a) .
